Thursday, Tibotec Pharmaceuticals announced results from two pivotal Phase 3, double-blind, randomized clinical trials comparing the efficacy, safety and tolerability of its investigational non-nucleoside reverse transcriptase inhibitor TMC278 or rilpivirine versus efavirenz, each administered once daily with a nucleoside/nucleotide background regimen in treatment-naive, HIV-1-infected adults.
The company said the global trials, known as ECHO and THRIVE, reached their primary objective, which was to demonstrate non-inferiority of TMC278 vs.
Tibotec has also entered into a license and collaboration agreement with Gilead Sciences, Inc. (GILD) for the development and commercialization of a once-daily, fixed-dose combination of TMC278 and Gilead's Truvada.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.